Third Rock commits up to $2.16 billion to antibody pact with Chinese startup Funnel
Venture firm Third Rock Ventures has formed an antibody discovery partnership with Chinese startup Funnel Biosciences worth up to $2.16 billion in potential payments.
via Endpoints News (@endpts.com)
#biotech #AI
Venture firm Third Rock Ventures has formed an antibody discovery partnership with Chinese startup Funnel Biosciences worth up to $2.16 billion in potential payments.
via Endpoints News (@endpts.com)
#biotech #AI
TechBio Today
A daily front page for people working where biotechnology, the biotech industry, and AI meet. News, publications, and preprints, briefed and linked to the original source.
www.techbiotoday.com
November 9, 2026 at 7:10 PM
Third Rock commits up to $2.16 billion to antibody pact with Chinese startup Funnel
Venture firm Third Rock Ventures has formed an antibody discovery partnership with Chinese startup Funnel Biosciences worth up to $2.16 billion in potential payments.
via Endpoints News (@endpts.com)
#biotech #AI
Venture firm Third Rock Ventures has formed an antibody discovery partnership with Chinese startup Funnel Biosciences worth up to $2.16 billion in potential payments.
via Endpoints News (@endpts.com)
#biotech #AI
Argenx buys Unnatural Products for $550 million upfront to acquire oral peptide platform
via Fierce Biotech
#biotech #AI
via Fierce Biotech
#biotech #AI
TechBio Today
A daily front page for people working where biotechnology, the biotech industry, and AI meet. News, publications, and preprints, briefed and linked to the original source.
www.techbiotoday.com
November 9, 2026 at 4:10 PM
Argenx buys Unnatural Products for $550 million upfront to acquire oral peptide platform
via Fierce Biotech
#biotech #AI
via Fierce Biotech
#biotech #AI
Are you a growth stage #TechBio company at Seed or Series A? Are you looking for the right support to take your company to the next level? Why not apply now for TechBio Boost! 👉 shorturl.at/u6XB3
Don’t miss your chance to be part of it.
#TechBioBoost #TechBio
Don’t miss your chance to be part of it.
#TechBioBoost #TechBio
November 4, 2026 at 10:57 AM
Are you a growth stage #TechBio company at Seed or Series A? Are you looking for the right support to take your company to the next level? Why not apply now for TechBio Boost! 👉 shorturl.at/u6XB3
Don’t miss your chance to be part of it.
#TechBioBoost #TechBio
Don’t miss your chance to be part of it.
#TechBioBoost #TechBio
Mirum antibody clears hepatitis D virus in 59% of patients in second Phase 3 study
via Fierce Biotech
#biotech
via Fierce Biotech
#biotech
TechBio Today
A daily front page for people working where biotechnology, the biotech industry, and AI meet. News, publications, and preprints, briefed and linked to the original source.
www.techbiotoday.com
November 10, 2026 at 4:10 PM
Mirum antibody clears hepatitis D virus in 59% of patients in second Phase 3 study
via Fierce Biotech
#biotech
via Fierce Biotech
#biotech
Merck drops Sutro-partnered solid tumor cytokine candidate
Merck has discontinued MK-1484, an engineered interleukin-2 agonist developed alongside Sutro Biopharma that was in a Phase 1 trial as a monotherapy and alongside Keytruda.
via Fierce Biotech
#biotech
Merck has discontinued MK-1484, an engineered interleukin-2 agonist developed alongside Sutro Biopharma that was in a Phase 1 trial as a monotherapy and alongside Keytruda.
via Fierce Biotech
#biotech
TechBio Today
A daily front page for people working where biotechnology, the biotech industry, and AI meet. News, publications, and preprints, briefed and linked to the original source.
www.techbiotoday.com
November 6, 2026 at 10:10 PM
Merck drops Sutro-partnered solid tumor cytokine candidate
Merck has discontinued MK-1484, an engineered interleukin-2 agonist developed alongside Sutro Biopharma that was in a Phase 1 trial as a monotherapy and alongside Keytruda.
via Fierce Biotech
#biotech
Merck has discontinued MK-1484, an engineered interleukin-2 agonist developed alongside Sutro Biopharma that was in a Phase 1 trial as a monotherapy and alongside Keytruda.
via Fierce Biotech
#biotech
Tokenized foundation model learns directly from continuous raw nanopore electrical signals
Researchers introduced Brieno, a self-supervised transformer model pretrained on continuous ionic current traces from 118 million raw nanopore sequencing reads.
via bioRxiv
#science #AI
Researchers introduced Brieno, a self-supervised transformer model pretrained on continuous ionic current traces from 118 million raw nanopore sequencing reads.
via bioRxiv
#science #AI
TechBio Today
A daily front page for people working where biotechnology, the biotech industry, and AI meet. News, publications, and preprints, briefed and linked to the original source.
www.techbiotoday.com
November 6, 2026 at 4:10 PM
Grok Bot + superintelligence + longévité + AI, un bien beau combo tech bros trumpisés dans ce CP de la techbio américaine Insilico insilico.com/news/pr9a97f...
Insilico Open-Sources 24/7 Personal Longevity Superintelligence to Turn Quantified-Self Data into Predictive Health States and Aging Research
Insilico announced the open-source release of Longevity Grok, the Personal Longevity Superintelligence (PLSI) and launched the website longevitygrok.si.
insilico.com
November 10, 2026 at 9:59 AM
Grok Bot + superintelligence + longévité + AI, un bien beau combo tech bros trumpisés dans ce CP de la techbio américaine Insilico insilico.com/news/pr9a97f...
Proximal Ventures closes $27.5 million fund for AI drug-service startups
Former SignalFire principal Sahir Raoof has raised a $27.5 million debut solo fund to back early-stage startups using machine learning to replace conventional biopharma contract services.
via TechCrunch (@techcrunch.com)
Former SignalFire principal Sahir Raoof has raised a $27.5 million debut solo fund to back early-stage startups using machine learning to replace conventional biopharma contract services.
via TechCrunch (@techcrunch.com)
TechBio Today
A daily front page for people working where biotechnology, the biotech industry, and AI meet. News, publications, and preprints, briefed and linked to the original source.
www.techbiotoday.com
November 10, 2026 at 10:10 PM
Proximal Ventures closes $27.5 million fund for AI drug-service startups
Former SignalFire principal Sahir Raoof has raised a $27.5 million debut solo fund to back early-stage startups using machine learning to replace conventional biopharma contract services.
via TechCrunch (@techcrunch.com)
Former SignalFire principal Sahir Raoof has raised a $27.5 million debut solo fund to back early-stage startups using machine learning to replace conventional biopharma contract services.
via TechCrunch (@techcrunch.com)
Pentagon removes WuXi AppTec from Chinese military blacklist after court injunction
The US Department of Defense removed contract research giant WuXi AppTec from its list of Chinese military companies following a court injunction.
via STAT (@statnews.com)
#biotech
The US Department of Defense removed contract research giant WuXi AppTec from its list of Chinese military companies following a court injunction.
via STAT (@statnews.com)
#biotech
TechBio Today
A daily front page for people working where biotechnology, the biotech industry, and AI meet. News, publications, and preprints, briefed and linked to the original source.
www.techbiotoday.com
November 9, 2026 at 10:10 PM
Pentagon removes WuXi AppTec from Chinese military blacklist after court injunction
The US Department of Defense removed contract research giant WuXi AppTec from its list of Chinese military companies following a court injunction.
via STAT (@statnews.com)
#biotech
The US Department of Defense removed contract research giant WuXi AppTec from its list of Chinese military companies following a court injunction.
via STAT (@statnews.com)
#biotech
FDA approves Bayer oral blood thinner Sunharbo to cut recurrent stroke risk
The FDA approved Bayer's once-daily pill Sunharbo, also known as asundexian, to lower the risk of recurrent ischemic strokes when used alongside antiplatelet therapy.
via BioPharma Dive
#biotech
The FDA approved Bayer's once-daily pill Sunharbo, also known as asundexian, to lower the risk of recurrent ischemic strokes when used alongside antiplatelet therapy.
via BioPharma Dive
#biotech
TechBio Today
A daily front page for people working where biotechnology, the biotech industry, and AI meet. News, publications, and preprints, briefed and linked to the original source.
www.techbiotoday.com
November 10, 2026 at 1:10 AM
FDA approves Bayer oral blood thinner Sunharbo to cut recurrent stroke risk
The FDA approved Bayer's once-daily pill Sunharbo, also known as asundexian, to lower the risk of recurrent ischemic strokes when used alongside antiplatelet therapy.
via BioPharma Dive
#biotech
The FDA approved Bayer's once-daily pill Sunharbo, also known as asundexian, to lower the risk of recurrent ischemic strokes when used alongside antiplatelet therapy.
via BioPharma Dive
#biotech
Anthropic expands wet-lab drug discovery footprint amid industry skepticism over AI timelines
via Yahoo Finance
#biotech #AI
via Yahoo Finance
#biotech #AI
TechBio Today
A daily front page for people working where biotechnology, the biotech industry, and AI meet. News, publications, and preprints, briefed and linked to the original source.
www.techbiotoday.com
November 7, 2026 at 1:10 AM
Anthropic expands wet-lab drug discovery footprint amid industry skepticism over AI timelines
via Yahoo Finance
#biotech #AI
via Yahoo Finance
#biotech #AI
Orphan Therapeutics Accelerator in-licenses shelved gene therapy for rare metabolic disorder
via GEN
#biotech #AI
via GEN
#biotech #AI
TechBio Today
A daily front page for people working where biotechnology, the biotech industry, and AI meet. News, publications, and preprints, briefed and linked to the original source.
www.techbiotoday.com
November 6, 2026 at 1:10 AM
Metis TechBio inks a landmark $1.1 billion agreement with Eli Lilly to pioneer AI-driven tissue-specific lipid nanoparticle drug delivery technologies.
Metis TechBio Partners With Eli Lilly in $1.1B AI Delivery Deal - GlobalePrism
Metis TechBio inks a landmark $1.1 billion agreement with Eli Lilly to pioneer AI-driven tissue-specific lipid nanoparticle drug delivery technologies.
globaleprism.com
November 2, 2026 at 7:45 PM
Metis TechBio inks a landmark $1.1 billion agreement with Eli Lilly to pioneer AI-driven tissue-specific lipid nanoparticle drug delivery technologies.
Sanofi terminates Nurix STAT6 degrader program shortly after Phase 1 entry
via Fierce Biotech
#biotech
via Fierce Biotech
#biotech
TechBio Today
A daily front page for people working where biotechnology, the biotech industry, and AI meet. News, publications, and preprints, briefed and linked to the original source.
www.techbiotoday.com
November 4, 2026 at 4:10 PM
Sanofi terminates Nurix STAT6 degrader program shortly after Phase 1 entry
via Fierce Biotech
#biotech
via Fierce Biotech
#biotech
Ipsen adopts Charles River virtual control groups to cut animal numbers in safety studies
via Fierce Biotech
#biotech #AI
via Fierce Biotech
#biotech #AI
TechBio Today
A daily front page for people working where biotechnology, the biotech industry, and AI meet. News, publications, and preprints, briefed and linked to the original source.
www.techbiotoday.com
November 4, 2026 at 10:10 PM
Ipsen adopts Charles River virtual control groups to cut animal numbers in safety studies
via Fierce Biotech
#biotech #AI
via Fierce Biotech
#biotech #AI
TechBio Today is a daily front page for AI-driven biology.
Every weekday morning: the news, papers, and preprints that changed something, each briefed in a few sentences with the specifics and linked to its source.
Top stories are posted here through the day. All of them arrive by email, free.
Every weekday morning: the news, papers, and preprints that changed something, each briefed in a few sentences with the specifics and linked to its source.
Top stories are posted here through the day. All of them arrive by email, free.
Subscribe to TechBio Today
Free by email, every weekday morning or once a week on Friday.
www.techbiotoday.com
November 1, 2026 at 12:00 AM
TechBio Today is a daily front page for AI-driven biology.
Every weekday morning: the news, papers, and preprints that changed something, each briefed in a few sentences with the specifics and linked to its source.
Top stories are posted here through the day. All of them arrive by email, free.
Every weekday morning: the news, papers, and preprints that changed something, each briefed in a few sentences with the specifics and linked to its source.
Top stories are posted here through the day. All of them arrive by email, free.
Revolution Medicines logs $198 million in Rasonque sales during first five weeks
Revolution Medicines reported $198 million in sales for Rasonque, its newly approved pan-RAS inhibitor pill for pancreatic cancer, across its initial five weeks on the US market.
via STAT
#biotech
Revolution Medicines reported $198 million in sales for Rasonque, its newly approved pan-RAS inhibitor pill for pancreatic cancer, across its initial five weeks on the US market.
via STAT
#biotech
TechBio Today
A daily front page for people working where biotechnology, the biotech industry, and AI meet. News, publications, and preprints, briefed and linked to the original source.
www.techbiotoday.com
November 5, 2026 at 4:10 PM
Recursion plans pivotal trial for rare genetic polyp drug following Phase 2 results
via GEN
#biotech #AI
via GEN
#biotech #AI
TechBio Today
A daily front page for people working where biotechnology, the biotech industry, and AI meet. News, publications, and preprints, briefed and linked to the original source.
www.techbiotoday.com
November 3, 2026 at 7:10 PM
10x Genomics adds Claude-driven analysis agents to Chromium instruments
10x Genomics launched Sentira Single Cell, a cloud-based conversational analysis tool powered by Anthropic's Claude models for users of its Chromium sequencing hardware.
via GEN
10x Genomics launched Sentira Single Cell, a cloud-based conversational analysis tool powered by Anthropic's Claude models for users of its Chromium sequencing hardware.
via GEN
TechBio Today
A daily front page for people working where biotechnology, the biotech industry, and AI meet. News, publications, and preprints, briefed and linked to the original source.
www.techbiotoday.com
November 2, 2026 at 8:20 PM
10x Genomics adds Claude-driven analysis agents to Chromium instruments
10x Genomics launched Sentira Single Cell, a cloud-based conversational analysis tool powered by Anthropic's Claude models for users of its Chromium sequencing hardware.
via GEN
10x Genomics launched Sentira Single Cell, a cloud-based conversational analysis tool powered by Anthropic's Claude models for users of its Chromium sequencing hardware.
via GEN
METiS TechBio, a Hong Kong-listed AI-powered drug delivery company, has entered a strategic research collaboration with Eli Lilly to develop novel lipid nanoparticle (LNP) technologies capable of delivering therapeutic payloads to specific tissues.
See more👇
thepharmanavigator.com/news/metis-a...
See more👇
thepharmanavigator.com/news/metis-a...
METiS and Lilly Partner to Develop AI-Designed, Tissue-Targeted LNPs - The Pharma Navigator
The strategic collaboration will provide Lilly access to METiS’ AI and nanomaterial science expertise as the company looks to strengthen its position in advanced drug delivery.
thepharmanavigator.com
November 4, 2026 at 1:54 PM
METiS TechBio, a Hong Kong-listed AI-powered drug delivery company, has entered a strategic research collaboration with Eli Lilly to develop novel lipid nanoparticle (LNP) technologies capable of delivering therapeutic payloads to specific tissues.
See more👇
thepharmanavigator.com/news/metis-a...
See more👇
thepharmanavigator.com/news/metis-a...
FDA grants tentative clearance for generic version of Gilead's long-acting HIV injection
The FDA granted tentative approval to Dr. Reddy's Laboratories to produce a generic formulation of lenacapavir, a twice-yearly capsid inhibitor for HIV prevention.
via STAT
#biotech
The FDA granted tentative approval to Dr. Reddy's Laboratories to produce a generic formulation of lenacapavir, a twice-yearly capsid inhibitor for HIV prevention.
via STAT
#biotech
TechBio Today
A daily front page for people working where biotechnology, the biotech industry, and AI meet. News, publications, and preprints, briefed and linked to the original source.
www.techbiotoday.com
November 3, 2026 at 4:10 PM
Greg will join a panel to discuss the EU's digital future alongside other EU ecosystem leaders. He’ll be discussing how Europe can play to its strengths in AI and digital healthcare, as well as build competitive and scalable techbio enterprise capabilities.
October 29, 2026 at 8:39 AM
Greg will join a panel to discuss the EU's digital future alongside other EU ecosystem leaders. He’ll be discussing how Europe can play to its strengths in AI and digital healthcare, as well as build competitive and scalable techbio enterprise capabilities.